- Home
- SISI vs DRMA Comparison
SISI vs DRMA Comparison
Compare SISI & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- DRMA
- Stock Information
- Founded
- SISI 1997
- DRMA 2014
- Country
- SISI China
- DRMA United States
- Employees
- SISI N/A
- DRMA N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- DRMA Health Care
- Exchange
- SISI Nasdaq
- DRMA Nasdaq
- Market Cap
- SISI 4.0M
- DRMA 4.5M
- IPO Year
- SISI 2016
- DRMA 2021
- Fundamental
- Price
- SISI $0.17
- DRMA $0.73
- Analyst Decision
- SISI
- DRMA Strong Buy
- Analyst Count
- SISI 0
- DRMA 1
- Target Price
- SISI N/A
- DRMA $3.00
- AVG Volume (30 Days)
- SISI 3.1M
- DRMA 117.8K
- Earning Date
- SISI 05-15-2025
- DRMA 08-06-2025
- Dividend Yield
- SISI N/A
- DRMA N/A
- EPS Growth
- SISI N/A
- DRMA N/A
- EPS
- SISI N/A
- DRMA N/A
- Revenue
- SISI $9,601,324.00
- DRMA N/A
- Revenue This Year
- SISI N/A
- DRMA N/A
- Revenue Next Year
- SISI N/A
- DRMA N/A
- P/E Ratio
- SISI N/A
- DRMA N/A
- Revenue Growth
- SISI 1133.26
- DRMA N/A
- 52 Week Low
- SISI $0.15
- DRMA $0.57
- 52 Week High
- SISI $28.32
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- SISI 30.10
- DRMA 55.76
- Support Level
- SISI $0.15
- DRMA $0.61
- Resistance Level
- SISI $0.19
- DRMA $0.74
- Average True Range (ATR)
- SISI 0.03
- DRMA 0.06
- MACD
- SISI 0.01
- DRMA 0.01
- Stochastic Oscillator
- SISI 26.75
- DRMA 68.58
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.